Nathan DM, Buse JB, Davidson MB, et al.
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 31: 173-175, 2008
Link

Heine RJ, Van Gaal LF, Johns D, et al.
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Ann Intern Med. 143: 559-569, 2005
Abstract

Aschner P, Kipnes MS, Lunceford JK, et al.
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
Diabetes Care 29: 2632-2637, 2006
Link

Bolen S, Feldman L, Vassy J, et al.
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
Ann Intern Med. 147, 386-399: 2007
Abstract

Brazg R, Xu L, Dalla Man C, et al.
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Diabetes Obes Metab. 9: 186-193, 2007
Link

Nauck MA, Meininger G, Sheng D, et al.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
Diabetes Obes Metab. 9: 194-205, 2007
Link

Nathan DM, Buse JB, Davidson MB, et al.
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 31: 173-175, 2008
Link

Monami M, Lamanna C, Marchionni N, Mannucci E.
Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis.
Diabetes Res Clin Pract. 79: 196-203, 2008
Abstract

Nauck MA, Kleine N, Orskov C, et al.
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
Diabetologia 36: 741-744, 1993
Abstract

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet 352: 837-853, 1998
Abstract

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 854-865, 1998
Abstract

Miyazaki Y, Mahankali A, Matsuda M, et al.
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
J Clin Endocrinol Metab. 87: 2784-2791, 2002
Link

Kavianipour M, Ehlers MR, Malmberg K, et al.
Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium.
Peptides 24: 569-578, 2003
Abstract

Yu M, Moreno C, Hoagland KM, et al.
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats.
J Hypertens. 21: 1125-1135, 2003
Abstract

Gutzwiller JP, Tschopp S, Bock A, et al.
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.
J Clin Endocrinol Metab. 89: 3055-3061, 2004
Link

Hanefeld M, Cagatay M, Petrowitsch T, et al.
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.
Eur Heart J. 25: 10-16, 2004
Link

Nikolaidis LA, Elahi D, Hentosz T, et al.
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110: 955-961, 2004
Link

Nikolaidis LA, Mankad S, Sokos GG, et al.
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Circulation 109: 962-965, 2004
Link

Nyström T, Gutniak MK, Zhang Q, et al.
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Am J Physiol Endocrinol Metab. 87: E1209-1215, 2004
Link

Thrainsdottir I, Malmberg K, Olsson A, et al.
Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure.
Diab Vasc Dis Res. 1: 40-43, 2004
Abstract

Bose AK, Mocanu MM, Carr RD, et al.
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151, 2005
Link

Dormandy JA, Charbonnel B, Eckland DJ, et al.
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Lancet 366: 1279-1289, 2005
Abstract

Nyström T, Gonon AT, Sjöholm A, Pernow J.
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 125: 173-177, 2005
Abstract

Blonde L, Klein EJ, Han J, et al.
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Diabetes Obes Metab. 8: 436-447, 2006
Link

Drucker DJ, Nauck MA.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Lancet 368: 1696-1705,
Abstract

Kahn SE, Haffner SM, Heise MA, et al.
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
N Engl J Med. 355: 2427-2443, 2006
Link

Amori RE, Lau J, Pittas AG.
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
JAMA 298: 194-206, 2007
Link

Bolen S, Feldman L, Vassy J, et al.
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
Ann Intern Med. 147: 386-399, 2007
Link

Giorgino F, Natalicchio A, Leonardini A, Laviola L.
Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complications.
Diabetes Res Clin Pract. 78 (S1): S59-S67, 2007
Abstract

Home PD, Pocock SJ, Beck-Nielsen H, et al.
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis
N Engl J Med. 357: 28-38, 2007
Link

Kim D, MacConell L, Zhuang D, et al.
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Diabetes Care 30: 1487-1493, 2007
Link

Nauck MA, Meininger G, Sheng D, et al.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
Diabetes Obes Metab. 9: 194-205, 2007
Link

ADVANCE Collaborative Group, Patel A, MacMahon S, et al.
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 358: 2560-2572, 2008
Link

DeFronzo RA, Okerson T, Viswanathan P, et al.
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
Curr Med Res Opin. 24: 2943-2952, 2008
Abstract

Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 359: 1577-1589, 2008
Abstract

Klonoff DC, Buse JB, Nielsen LL, et al.
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
Curr Med Res Opin. 24: 275-286, 2008
Abstract

Nauck M, Stöckmann F, Ebert R, Creutzfeldt W.
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
Diabetologia 29: 46-52, 1986
Abstract

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 854-865, 1998
Abstract

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet 352: 837-853, 1998
Abstract

Weyer C, Bogardus C, Mott DM, Pratley RE.
The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.
J Clin Invest. 104: 787-794, 1999
Link

Toft-Nielsen MB, Damholt MB, Madsbad S, et al.
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
J Clin Endocrinol Metab. 86: 3717-3723, 2001
Link

Chiasson JL, Josse RG, Gomis R, et al.
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Lancet 359: 2072-2077, 2002
Abstract

Knowler WC, Barrett-Connor E, Fowler SE, et al.
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
N Engl J Med. 346: 393-403, 2002
Link

Butler AE, Janson J, Bonner-Weir S, et al.
Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.
Diabetes 52: 102-110, 2003
Link

DREAM Trial Investigators, Gerstein HC, Yusuf S, et al.
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
Lancet 368: 1096-1105, 2006
Abstract

Giorgino F, Laviola L, Leonardini A, Natalicchio A.
GLP-1: a new approach for type 2 diabetes therapy.
Diabetes Res Clin Pract 74 (S2): S152-S155, 2006
Abstract

Kahn SE, Haffner SM, Heise MA, et al.
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
N Engl J Med. 355: 2427-2443, 2006
Link

Prentki M, Nolan CJ.
Islet beta cell failure in type 2 diabetes.
J Clin Invest. 116: 1802-1812, 2006
Link

ADVANCE Collaborative Group, Patel A, MacMahon S, et al.
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 358: 2560-2572, 2008
Link

DeFronzo RA, Okerson T, Viswanathan P, et al.
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
Curr Med Res Opin. 24: 2943-2952, 2008
Abstract

Klonoff DC, Buse JB, Nielsen LL, et al.
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
Curr Med Res Opin. 24: 275-286, 2008
Abstract

Lupi R, Mancarella R, Del Guerra S, et al.
Effects of exendin-4 on islets from type 2 diabetes patients.
Diabetes Obes Metab. 10: 515-519, 2008
Abstract

Pinelli NR, Cha R, Brown MB, Jaber LA.
Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
Ann Pharmacother. 42: 1541-51, 2008
Abstract

Rosenstock J, Foley JE, Rendell M, et al.
Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Diabetes Care 31: 30-35, 2008
Link

Utzschneider KM, Tong J, Montgomery B, et al.
The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 31: 108-113, 2008
Link